These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 34699691)

  • 1. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.
    Ma L; Diao B; Huang Z; Wang B; Yu J; Meng X
    Cancer Commun (Lond); 2021 Dec; 41(12):1314-1330. PubMed ID: 34699691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of Immune Checkpoint Inhibitors in EGFR Mutant 
Advanced Non-small Cell Lung Cancer].
    Zheng Y; Jiang W; Li J; Dai L; Chen D; Li Y; Huang L; Wang M
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):671-677. PubMed ID: 36172732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
    Liu Y; Miao J
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):934-942. PubMed ID: 38163979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
    Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
    Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
    Qiao M; Jiang T; Liu X; Mao S; Zhou F; Li X; Zhao C; Chen X; Su C; Ren S; Zhou C
    J Thorac Oncol; 2021 Aug; 16(8):1267-1288. PubMed ID: 33915248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
    Lin A; Wei T; Meng H; Luo P; Zhang J
    Mol Cancer; 2019 Sep; 18(1):139. PubMed ID: 31526368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
    Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 12. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
    Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y
    Front Immunol; 2022; 13():931718. PubMed ID: 35990690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
    Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.
    Trabelsi Grati O; Zemoura L; Nhy C; Daniel C; Melaabi S; Callens C; Gauthier Villars M; Bièche I; Girard N
    Lung Cancer; 2022 Dec; 174():186-187. PubMed ID: 36156246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to 
Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].
    Li J; Yao X; Qiu L; Zhang R; Wang G
    Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):392-399. PubMed ID: 37316449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in advanced non-small-cell lung cancer with
    Liu F; Yuan X; Jiang J; Chu Q
    Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
    Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.